DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award

Defense Health Agency Contracting Activity - DHACA · HT942526DMDRPCTRA · Deadline: September 18, 2026

This listing sits under an agency-wide umbrella (CFDA 12.420, Military Medical Research and Development — ~1078 awards/yr across many separate competitions). Program-level statistics would describe the whole umbrella, not this competition, so we don't show them as if they were this opportunity's history. Any tool showing "award history" for this listing at the program level is describing the umbrella.

Listing summary

Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical …

Eligibility: Unrestricted · Categories: Science and Technology · official listing ↗

This is the free preview

The full brief adds winner tables, recipient breakdowns, the printable "prepared for your client" version, and CSV export — plus a matched-grants list for your client's profile. Client Packet $79 or Pro subscription →

Sources: NIH RePORTER (opportunity-exact) and USAspending (program-level), labeled per section. GrantsDue computes summaries only; verify anything critical against the originals. Methodology.